Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Research article

Multi-targeting chemoprevention of Chinese herb formula Yanghe Huayan decoction on experimentally induced mammary tumorigenesis

Authors: Jingwei Li, Xiaofei Liu, Hongzhi Chen, Ziyuan Sun, Hanhan Chen, Lei Wang, Xiaohui Sun, Xiangqi Li

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

Development of safe and effective chemopreventive agents is a winning strategy in reducing the morbidity and mortality of breast cancer. The current study was to investigate the mechanism-based chemopreventive potential of a Chinese herb formula Yanghe Huayan (YHHY) Decoction on the classical 7,12-dimethylbenz(a)anthracene (DMBA) induced rat mammary carcinogenesis model.

Methods

Female Sprague-Dawley rats at 42 days of age were orally administered with a human equivalent dose of YHHY Decoction at 0.02 ml/g (10 mg/ml) once daily, starting 1 wk. before and 4 wks following DMBA treatment. Mammary tumor occurrence was monitored every day. The length of time before palpable tumor is examined is defined as tumor-free survival time. High performance liquid chromatography (HPLC) analyses were adopted to identify major chemical compositions of the decoction. Following bioinformatics data mining and experimental analyses were performed to demonstrate the underlying mechanism of action.

Results

DMBA animals receiving YHHY Decoction exhibited a significant delay (P = 0.014) and in some animals prevention (P = 0.046) of tumor occurrence without obvious toxicity. Oncogenic myc activation was significantly suppressed in the DMBA-induced rats by the YHHY treatment. Eight major chemical compositions of the decoction were identified and were shown to interfere with multiple tumorigenic pathways simultaneously in the mammary tumors, including inducing tumor apoptosis and up-regulating pro-apoptotic protein Bax and down-regulating anti-apoptotic protein Bcl-2; suppressing abnormal cell proliferation and the MAPK/ERK, PI3K/AKT signalings; blocking neo-angiogenesis and the VEGF/KDR signaling, and inhibiting oxidative stress in the mammary tumors.

Conclusion

The multi-components and multi-targeting properties of the YHHY Decoction support its use as a potent chemopreventive drug in breast cancer.
Literature
1.
Sinn HP, Elsawaf Z, Helmchen B, Aulmann S. Early breast Cancer precursor lesions: lessons learned from molecular and clinical studies. Breast Care (Basel). 2010;5(4):218–26.CrossRef
2.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51.PubMedCrossRef
3.
Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229–37.PubMedCrossRef
4.
Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007;25(19):2671–7.PubMedCrossRef
5.
Warnberg F, Yuen J, Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet. 2000;355(9205):724–5.PubMedCrossRef
6.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90(18):1371–88.CrossRefPubMed
7.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–97.PubMedCrossRef
8.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.CrossRef
9.
Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.PubMedCrossRef
10.
Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(7):1053–60.PubMedPubMedCentralCrossRef
11.
Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EM, Polubriaginof F, Parmigiani G, Garber JE, Smith BL, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136(3):627–33.PubMedCrossRef
12.
Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clinical Oncol. 2010;28(18):3090–5.CrossRef
13.
Lebeau A. Precancerous lesions of the breast. Breast Care (Basel). 2010;5(4):204–6.CrossRef
14.
15.
Normile D. DRUG DISCOVERY. Nobel for antimalarial drug highlights East-West divide. Science. 2015;350(6258):265.PubMedCrossRef
16.
The Lancet O. Rethinking traditional Chinese medicines for cancer. Lancet Oncol. 2015;16(15):1439.CrossRef
17.
Kong DX, Li XJ, Zhang HY. Where is the hope for drug discovery? Let history tell the future. Drug Discov Today. 2009;14(3–4):115–9.PubMedCrossRef
18.
Ling CQ, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med. 2014;12(4):331–5.PubMedCrossRef
19.
Jo EH, Kim SH, Ra JC, Kim SR, Cho SD, Jung JW, Yang SR, Park JS, Hwang JW, Aruoma OI, et al. Chemopreventive properties of the ethanol extract of chinese licorice (Glycyrrhiza uralensis) root: induction of apoptosis and G1 cell cycle arrest in MCF-7 human breast cancer cells. Cancer Lett. 2005;230(2):239–47.PubMedCrossRef
20.
Gu Y, Korbel C, Scheuer C, Nenicu A, Menger MD, Laschke MW. Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model. Oncotarget. 2016;7(5):5258–72.PubMedCrossRef
21.
Ray A, Vasudevan S, Sengupta S. 6-Shogaol inhibits breast Cancer cells and stem cell-like spheroids by modulation of notch signaling pathway and induction of Autophagic cell death. PLoS One. 2015;10(9):e0137614.PubMedPubMedCentralCrossRef
22.
Kwon HK, Hwang JS, So JS, Lee CG, Sahoo A, Ryu JH, Jeon WK, Ko BS, Im CR, Lee SH, et al. Cinnamon extract induces tumor cell death through inhibition of NFkappaB and AP1. BMC Cancer. 2010;10:392.PubMedPubMedCentralCrossRef
23.
24.
Miller JA. Carcinogenesis by chemicals: an overview--G. H. A. Clowes memorial lecture. Cancer Res. 1970;30(3):559–76.PubMed
25.
Pitot HC DY: Chemical carcinogenesis. In: Casarett and Doull’s Toxicology. edn. Edited by CD K. New York: McGraw-Hill; 1996: 201–267.
26.
Russo J, Russo IH. Experimentally induced mammary tumors in rats. Breast Cancer Res Treat. 1996;39(1):7–20.PubMedCrossRef
27.
Heffelfinger SC, Gear RB, Taylor K, Miller MA, Schneider J, LaDow K, Warshawsky D. DMBA-induced mammary pathologies are angiogenic in vivo and in vitro. Lab Investig. 2000;80(4):485–92.PubMedCrossRef
28.
Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff RD, Xiao ZX, et al. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol. 2005;33(6):726–37.PubMedCrossRef
29.
Russo J, Russo IH. Biological and molecular bases of mammary carcinogenesis. Lab Investig. 1987;57(2):112–37.PubMed
30.
Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Investig. 1990;62(3):244–78.PubMed
31.
Russo J, Russo IH. Atlas and histologic classification of tumors of the rat mammary gland. J Mammary Gland Biol Neoplasia. 2000;5(2):187–200.PubMedCrossRef
32.
Batcioglu K, Uyumlu AB, Satilmis B, Yildirim B, Yucel N, Demirtas H, Onkal R, Guzel RM, Djamgoz MB. Oxidative stress in the in vivo DMBA rat model of breast cancer: suppression by a voltage-gated sodium channel inhibitor (RS100642). Basic Clin Pharmacol Toxicol. 2012;111(2):137–41.PubMed
33.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265–75.PubMed
34.
McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969;244(22):6049–55.PubMed
35.
Catalase LH. Methods in enzymatic analysis. Weinhelm-New York: Verlag-Chemie-Academic Press; 1963.
36.
Miki N, Nagano M, Kuriyama K. Catalase activates cerebral granylate cyclase in the presence of sodium azide. Biochem Biophys Res Commun. 1976;72(3):952–9.PubMedCrossRef
37.
Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86(1):271–8.PubMedCrossRef
38.
Sastry KV, Moudgal RP, Mohan J, Tyagi JS, Rao GS. Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Anal Biochem. 2002;306(1):79–82.PubMedCrossRef
39.
Schwertner HA, Rios DC. High-performance liquid chromatographic analysis of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol in ginger-containing dietary supplements, spices, teas, and beverages. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;856(1–2):41–7.PubMedCrossRef
40.
Zhang CH, Yu Y, Liang YZ, Chen XQ. Purification, partial characterization and antioxidant activity of polysaccharides from Glycyrrhiza uralensis. Int J Biol Macromol. 2015;79:681–6.PubMedCrossRef
41.
Zong Y, Wang Y, Li H, Li N, Zhang H, Sun J, Niu X, Gao X. Simultaneous quantification and splenocyte-proliferating activities of nucleosides and bases in Cervi cornu Pantotrichum. Pharmacogn Mag. 2014;10(40):391–7.PubMedPubMedCentralCrossRef
42.
Zhang X, Wang R, An R, Wu X, Wang X, Li Y. Simultaneous determination of five constituents in Scrophularia ningpoensis by HPLC. Zhongguo Zhong Yao Za Zhi. 2011;36(6):709–11.PubMed
43.
Seo CS, Shin HK. Simultaneous determination of nine marker compounds in the traditional Korean medicine, Dangguisu-san by high-performance liquid chromatography. Pharmacogn Mag. 2015;11(43):555–61.PubMedPubMedCentralCrossRef
44.
Ma R, Song G, You W, Yu L, Su W, Liao M, Zhang Y, Huang L, Zhang X, Yu T. Anti-microtubule activity of tubeimoside I and its colchicine binding site of tubulin. Cancer Chemother Pharmacol. 2008;62(4):559–68.PubMedCrossRef
45.
Tsao R, Yu Q, Potter J, Chiba M. Direct and simultaneous analysis of sinigrin and allyl isothiocyanate in mustard samples by high-performance liquid chromatography. J Agric Food Chem. 2002;50(17):4749–53.PubMedCrossRef
46.
Kenney NJ, Smith GH, Lawrence E, Barrett JC, Salomon DS. Identification of stem cell units in the terminal end bud and Duct of the mouse mammary gland. J Biomed Biotechnol. 2001;1(3):133–43.PubMedPubMedCentralCrossRef
47.
Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med. 2014;4:a014241.
48.
Chung MW, Tsoutsman T, Semsarian C. Hypertrophic cardiomyopathy: from gene defect to clinical disease. Cell Res. 2003;13(1):9–20.PubMedCrossRef
49.
Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M. Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer. 1996;74(10):1586–91.PubMedPubMedCentralCrossRef
50.
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359–71.PubMedCrossRef
51.
52.
Dougher-Vermazen M, Hulmes JD, Bohlen P, Terman BI. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun. 1994;205(1):728–38.PubMedCrossRef
53.
Giri U, Sharma SD, Abdulla M, Athar M. Evidence that in situ generated reactive oxygen species act as a potent stage I tumor promoter in mouse skin. Biochem Biophys Res Commun. 1995;209(2):698–705.PubMedCrossRef
54.
Kurokawa Y, Takamura N, Matsushima Y, Imazawa T, Hayashi Y. Studies on the promoting and complete carcinogenic activities of some oxidizing chemicals in skin carcinogenesis. Cancer Lett. 1984;24(3):299–304.PubMedCrossRef
55.
56.
57.
58.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81.PubMedCrossRef
59.
Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–82.PubMedCrossRef
60.
61.
Sesti F, Tsitsilonis OE, Kotsinas A, Trougakos IP. Oxidative stress-mediated biomolecular damage and inflammation in tumorigenesis. In Vivo. 2012;26(3):395–402.PubMed
62.
63.
Zhou X, Seto SW, Chang D, Kiat H, Razmovski-Naumovski V, Chan K, Bensoussan A. Synergistic effects of Chinese herbal medicine: a comprehensive review of methodology and current research. Front Pharmacol. 2016;7:201.PubMedPubMedCentral
64.
Jolad SD, Lantz RC, Chen GJ, Bates RB, Timmermann BN. Commercially processed dry ginger (Zingiber officinale): composition and effects on LPS-stimulated PGE2 production. Phytochemistry. 2005;66(13):1614–35.PubMedCrossRef
65.
Ling H, Yang H, Tan SH, Chui WK, Chew EH. 6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-kappaB activation. Br J Pharmacol. 2010;161(8):1763–77.PubMedPubMedCentralCrossRef
66.
Tan BS, Kang O, Mai CW, Tiong KH, Khoo AS, Pichika MR, Bradshaw TD, Leong CO. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor gamma (PPARgamma). Cancer Lett. 2013;336(1):127–39.PubMedCrossRef
67.
Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, Huang J, Liu JR. Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med. 2007;7:44.PubMedPubMedCentralCrossRef
68.
Liu L, Hudgins WR, Shack S, Yin MQ, Samid D. Cinnamic acid: a natural product with potential use in cancer intervention. Int J Cancer. 1995;62(3):345–50.PubMedCrossRef
69.
Hao W, Wang S, Zhou Z. Tubeimoside-1 (TBMS1) inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway. Int J Clin Exp Pathol. 2015;8(10):12075–83.PubMedPubMedCentral
70.
Zhang Y, Xu X, He P. Tubeimoside-1 inhibits proliferation and induces apoptosis by increasing the Bax to Bcl-2 ratio and decreasing COX-2 expression in lung cancer A549 cells. Mol Med Rep. 2011;4(1):25–9.PubMed
71.
Thejass P, Kuttan G. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate. Integr Cancer Ther. 2007;6(4):389–99.PubMedCrossRef
72.
Xu H and Xu X. Polysaccharide, a Potential Anti-Cancer Drug with High Efficacy and Safety. J Oncol Res Treat. 2016;1:110.
73.
Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol. 2016;29:7–16.PubMedCrossRef
Metadata
Title
Multi-targeting chemoprevention of Chinese herb formula Yanghe Huayan decoction on experimentally induced mammary tumorigenesis
Authors
Jingwei Li
Xiaofei Liu
Hongzhi Chen
Ziyuan Sun
Hanhan Chen
Lei Wang
Xiaohui Sun
Xiangqi Li
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2456-1

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue

Research article

The extract from Agkistrodon halys venom protects against lipopolysaccharide (LPS)-induced myocardial injury

Research article

Hepato-protective effects of Glossogyne tenuifolia in Streptozotocin-nicotinamide-induced diabetic rats on high fat diet

Research article

An ethnobotanical study of medicinal plants used to treat skin diseases in northern Pakistan

Research article

Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model

Research article

Comparison of pharmacological properties and phytochemical constituents of in vitro propagated and naturally occurring liverwort Lunularia cruciata

Research article

Larrea divaricata Cav. aqueous extract and nordihydroguariaretic acid modulate oxidative stress in submandibular glands of diabetic rats: a buccal protective in diabetes